Monitoring Report: GLP-1 RA Prescribing Trends – December 2025 Data

Samuel Gratzl, PhD

Karen Gilbert Farrar, PhD

Duy Do, PhD

Nina Masters, MPH, PhD

Brianna M Goodwin Cartwright, MS

Affiliations: All authors are affiliated with Truveta, Inc.

Corresponding author:
Brianna Cartwright
Truveta, Inc
1745 114th Ave SE, Bellevue, WA 98004
Email: briannac@truveta.com

Abstract

Background: Limited recent data exist on prescribing patterns and patient characteristics for glucagon-like peptide 1 receptor agonists (GLP-1 RAs), an important drug class used as anti-diabetic medication (ADM) for patients with type 2 diabetes mellitus (T2D) and/or anti-obesity medication (AOM) in patients with overweight or obesity.

For brevity, we use the term GLP-1 RA to refer to both GLP-1 RA and dual GLP-1 RA/GIP medications.

Objective: To describe recent trends in prescribing and dispensing of GLP-1-based medications in the US.

Methods: Using a subset of real-world electronic health record (EHR) data from Truveta, a growing collective of health systems that provide more than 18% of all daily clinical care in the US, we identified people who were prescribed a GLP-1-based medication between January 01, 2019 and December 31, 2025. We describe prescribing volumes and patient characteristics over time, by medication, and by FDA-labeled use. Among the subset of patients for whom post-prescription dispensing data is available, we describe the proportion and characteristics of patients who were and were not dispensed a GLP-1 RA following their prescription.

Results: 2,185,238 patients were prescribed a GLP-1 RA between January 2019 and December 2025, with 11,194,909 total prescriptions during this period. Among first-time prescriptions for which use could be established, 69.1% were ADMs and 30.9% were AOMs. Overall prescribing rates (GLP-1 RA prescriptions per total prescriptions) increased slightly from September to December 2025 (+5.02%); however, first-time prescribing rates declined over the same period (-6.62%). As of December 2025, GLP-1 RA prescriptions account for more than 7% of all prescriptions.

Trends in Prescribing







Date	GLP-1 RA	Semaglutide	Tirzepatide	Liraglutide	Dulaglutide	Other
Overall						
September 2025	6.75%	2.74%	3.68%	0.07%	0.39%	0.02%
December 2025	7.08%	2.72%	4.05%	0.08%	0.37%	0.02%
Change (percentage)	+5.02%	-0.81%	+10.03%	+11.68%	-5.74%	-8.41%
Difference (percentage points)	+0.34%	-0.02%	+0.37%	+0.01%	-0.02%	-0.00%
ADM						
September 2025	3.32%	1.19%	1.76%	0.00%	0.39%	0.02%
December 2025	3.45%	1.18%	1.91%	0.00%	0.37%	0.02%
Change (percentage)	+3.81%	-0.25%	+8.67%	+13.20%	-5.74%	-8.41%
Difference (percentage points)	+0.13%	-0.00%	+0.15%	+0.00%	-0.02%	-0.00%
AOM						
September 2025	2.26%	0.83%	1.47%	0.02%	n/a	n/a
December 2025	2.49%	0.84%	1.67%	0.02%	n/a	n/a

Date	GLP-1 RA	Semaglutide	Tirzepatide	Liraglutide	Dulaglutide	Other
Change (percentage)	+10.07%	+2.27%	+13.78%	+24.77%		
Difference (percentage points)	+0.23%	+0.02%	+0.20%	+0.00%		
Unknown						
September 2025	1.55%	0.82%	0.69%	0.05%	n/a	n/a
December 2025	1.56%	0.78%	0.74%	0.05%	n/a	n/a
Change (percentage)	+0.58%	-4.61%	+6.36%	+6.42%		
Difference (percentage points)	+0.01%	-0.04%	+0.04%	+0.00%		

- Overall prescribing rates (GLP-1 RA prescriptions per total prescriptions) in December 2025 increased slightly relative to September 2025 (+5.02%) and now account for more than 7% of all prescriptions.
- Month-over-month ADM prescribing increased in October, decreased in November, and increased again in December 2025. ADM prescribing in December 2025 was about the same as September 2025 (+3.81%).
- AOM prescribing increased in December 2025 compared to September 2025 (+10.07%).
- Tirzepatide remained the leading AOM and ADM by prescription volume and showed the largest increase in total prescribing from September to December 2025.

Trends in First-Time Prescribing





Date	GLP-1 RA	Semaglutide	Tirzepatide	Liraglutide	Dulaglutide	Other
Overall						
September 2025	1.45%	0.61%	0.78%	0.01%	0.06%	0.00%
December 2025	1.36%	0.54%	0.77%	0.01%	0.04%	0.00%
Change (percentage)	-6.62%	-11.77%	-1.56%	+7.24%	-24.03%	-12.38%
Difference (percentage points)	-0.10%	-0.07%	-0.01%	+0.00%	-0.01%	-0.00%
ADM						
September 2025	0.54%	0.21%	0.27%	0.00%	0.06%	0.00%
December 2025	0.47%	0.17%	0.25%	0.00%	0.04%	0.00%
Change (percentage)	-13.31%	-19.98%	-5.90%	-29.30%	-24.03%	-12.38%
Difference (percentage points)	-0.07%	-0.04%	-0.02%	-0.00%	-0.01%	-0.00%
AOM						
September 2025	0.55%	0.18%	0.37%	0.00%	n/a	n/a
December 2025	0.54%	0.17%	0.37%	0.00%	n/a	n/a
Change (percentage)	-1.00%	-4.53%	+0.43%	+44.40%		
Difference (percentage points)	-0.01%	-0.01%	+0.00%	+0.00%		
Unknown						
September 2025	0.39%	0.22%	0.16%	0.01%	n/a	n/a
December 2025	0.37%	0.20%	0.17%	0.01%	n/a	n/a
Change (percentage)	-4.22%	-9.70%	+2.90%	+3.58%		
Difference (percentage points)	-0.02%	-0.02%	+0.00%	+0.00%		

- First-time prescribing rates (first-time GLP-1 RA prescriptions per total prescriptions) in December 2025 decreased, relative to September 2025 (-6.62%).
- First-time prescribing of ADMs decreased in December 2025, relative to September 2025 (-13.31%).
- First-time prescribing of AOMs was about the same in December 2025, relative to September 2025 (-1.00%).

Trends in Dispensing





Date	GLP-1 RA	Semaglutide	Tirzepatide	Liraglutide	Dulaglutide	Other
Overall						
June 2025	52.86%	51.17%	52.30%	56.82%	76.06%	71.84%
September 2025	54.71%	55.31%	52.43%	57.05%	80.09%	71.67%
Change (percentage)	+3.50%	+8.08%	+0.25%	+0.41%	+5.29%	-0.25%
Difference (percentage points)	+1.85%	+4.14%	+0.13%	+0.23%	+4.03%	-0.18%
ADM						
June 2025	71.08%	69.43%	71.27%	76.92%	76.06%	71.84%
September 2025	72.53%	71.93%	71.50%	79.31%	80.09%	71.67%
Change (percentage)	+2.04%	+3.59%	+0.32%	+3.10%	+5.29%	-0.25%
Difference (percentage points)	+1.45%	+2.49%	+0.23%	+2.39%	+4.03%	-0.18%
AOM						
June 2025	46.82%	47.15%	46.61%	54.88%	n/a	n/a
September 2025	47.50%	53.39%	44.68%	58.73%	n/a	n/a
Change (percentage)	+1.45%	+13.23%	-4.14%	+7.02%		
Difference (percentage points)	+0.68%	+6.24%	-1.93%	+3.85%		
Unknown						
June 2025	37.71%	37.99%	36.67%	56.47%	n/a	n/a
September 2025	38.56%	40.50%	35.08%	54.17%	n/a	n/a
Change (percentage)	+2.25%	+6.58%	-4.36%	-4.08%		

Date	GLP-1 RA	Semaglutide	Tirzepatide	Liraglutide	Dulaglutide	Other
Difference (percentage points)	+0.85%	+2.50%	-1.60%	-2.30%		

- During the full time period, 70.7% of GLP-1 RA prescriptions had a dispense within 60 days of their prescription (e.g., were initiated within 60 days).
- For patients first prescribed an ADM in September 2025, 72.5% filled a GLP-1 RA within 60 days. Initiation rates for ADM GLP-1 RA are about the same in September 2025, relative to June 2025 (+2.04%).
- For patients first prescribed an AOM in September 2025, 47.5% filled a GLP-1 RA within 60 days. Initiation rates for AOM GLP-1 RA are about the same in September 2025, relative to June 2025 (+1.45%).

About this report

This report provides recent trends in the prescribing and dispensing of glucagon-like peptide-1 receptor agonist (GLP-1 RAs)-based medications, including dual GLP-1 RA/gastric inhibitory polypeptide (GIP) over time, by medication, and by FDA-labeled use. We used near real-time, aggregated electronic health record (EHR) data from a collective of US healthcare systems to describe prescribing and dispensing of GLP-1 RA medications from January 2019 to December 2025.

Introduction

Obesity and type 2 diabetes mellitus (T2D) are interconnected epidemics with a high prevalence and individual and combined negative impacts on health (CDC, 2020, Hales, 2020). Glucagon-like peptide-1 receptor agonist (GLP-1 RAs) -based medications, including dual GLP-1 RA/gastric inhibitory polypeptide (GIP), have been shown to improve glycemic control in patients with T2D and reduce weight in patients with and without T2D (Davies, 2015, Davies, 2021, Garvey, 2023, Jastreboff, 2022, Wilding, 2023, Yeh, 2023). GLP-1 RA have also demonstrated cardiovascular benefit in patients with and without T2D (Lincoff, 2023, Ussher, 2023).

Interest in these medications has recently accelerated, largely for their weight-loss effects; however, limited empiric data exist on prescribing, dispensing, and patient characteristics. Access to and use of GLP-1 RA may be impacted by high cost, limited insurance coverage for patients without T2D and medication shortages.

Methods

Data

We evaluated prescribing and dispensing of GLP-1 RAs between January 2019 and December 2025 using a subset of Truveta Data. Truveta provides access to continuously updated, linked, and de-identified electronic health record (EHR) from a collective of US health care systems that provide 18% of all daily clinical care in the US, including structured information on demographics, encounters, diagnoses, vital signs (e.g., weight, BMI, blood pressure), medication requests (prescriptions), medication administration, laboratory and diagnostic tests and results (e.g., HbA1c tests and values), and procedures. Updated EHR data are provided daily to Truveta by member health care systems. In addition to EHR data for care delivered within Truveta member health care systems, medication dispensing and social drivers of health (SDOH)

information are made available through linked third-party data. Medication dispense (via e-prescribing data) includes fills for prescriptions written both within and outside Truveta member health care systems, providing greater observability into patients' medication history. Medication dispense histories are updated at the time of the encounter and include fill dates, NDC or RxNorm codes, quantity dispensed, and days of medication supplied.

Population

We identified GLP-1 RA prescriptions (medication requests) and dispenses among adults using RxNorm and NDC codes for dulaglutide, exenatide, liraglutide, lixisenatide, semaglutide, and tirzepatide. Exenatide and lixisenatide were grouped as 'other' given small relative sizes. Brands were identified when possible using RxNorm and NDC codes. Brands labeled for treatment of T2D were classified as ADMs and brands labeled for treatment of overweight and obesity were classified as AOMs. When brand could not be established, the labeled use was classified as unknown.

Prescribing Analysis

Characteristics of patients ever prescribed a GLP-1 RA were summarized, including demographics, social drivers of health (SDOH), and presence of T2D and/or overweight or obesity. Characteristics are provided by medication and by year of first prescription.

Overall and first-time prescribing rates of GLP-1 RA were summarized over time by medication and labeled use. The prescribing rate was calculated monthly as the number of patients with a GLP-1 RA prescription divided by the number of patients with any prescription in the month. Absolute differences and percentage changes in the rate of GLP-1 RA prescribing over the most recent 3-month period were summarized overall and by medication and labeled use.

Dispensing Analysis

We describe the proportion of GLP-1 RA prescriptions (overall and first-time) with a dispense occurring within 60 days. Dispensing analyses were restricted to prescriptions for which complete 60-day dispensing outcomes could be observed. Dispensing outcomes were considered observable if (1) a dispense was recorded in the 60 days following the prescription, and/or (2) an encounter took place after the 60-day period ended (at which time any dispenses would be observed). To allow sufficient follow-up, we report dispensing with a 90-day delay. Given shortages and expected substitutions at the pharmacy, we considered the dispense of any GLP-1 RA , which could differ from the prescribed GLP-1 RA.

We plot the proportion of prescriptions (overall and first-time) dispensed within 60 days over time, by medication and use. Differences in dispensing were expected between ADMs and AOMs given ADMs are typically covered by insurance, whereas insurance coverage for AOMs is limited. As such, we provide dispensing rates stratified by FDA labeled use. Further, we stratify dispensing by age 65+ vs. 18-64 as a proxy for Medicare coverage. Medicare never provides coverage for AOMs, whereas commercial insurers may.

Results

Overall population

The demographics of patients by first-prescribed medication are as follows:

Table 1: Patient Characteristics by First-Prescribed GLP-1 RA Medication.

	Semaglutide	Tirzepatide	Liraglutide	Dulaglutide	Other	Overall
N	1,149,803 (100.00%)	566,451 (100.00%)	99,602 (100.00%)	270,383 (100.00%)	26,544 (100.00%)	2,112,783 (100.00%)
Age Group						
18-44	307,481 (26.74%)	179,814 (31.74%)	29,993 (30.11%)	40,187 (14.86%)	2,740 (10.32%)	560,215 (26.52%)
45-64	552,572 (48.06%)	275,689 (48.67%)	48,469 (48.66%)	135,341 (50.06%)	11,804 (44.47%)	1,023,875 (48.46%)
65+	289,750 (25.20%)	110,948 (19.59%)	21,140 (21.22%)	94,855 (35.08%)	12,000 (45.21%)	528,693 (25.02%)
Sex						
Female	752,397 (65.44%)	380,259 (67.13%)	70,295 (70.58%)	147,782 (54.66%)	13,766 (51.86%)	1,364,499 (64.58%)
Male	397,406 (34.56%)	186,192 (32.87%)	29,307 (29.42%)	122,601 (45.34%)	12,778 (48.14%)	748,284 (35.42%)
Race						
White	827,579 (71.98%)	416,992 (73.61%)	71,944 (72.23%)	182,423 (67.47%)	19,370 (72.97%)	1,518,308 (71.86%)
Black or African American	177,932 (15.47%)	73,070 (12.90%)	17,289 (17.36%)	50,645 (18.73%)	3,809 (14.35%)	322,745 (15.28%)
Asian	24,563 (2.14%)	11,222 (1.98%)	1,374 (1.38%)	6,213 (2.30%)	521 (1.96%)	43,893 (2.08%)
Unknown	74,323 (6.46%)	42,747 (7.55%)	5,715 (5.74%)	18,510 (6.85%)	1,829 (6.89%)	143,124 (6.77%)

	Semaglutide	Tirzepatide	Liraglutide	Dulaglutide	Other	Overall
Native Hawaiian or Other Pacific Islander	3,250 (0.28%)	1,489 (0.26%)	261 (0.26%)	922 (0.34%)	73 (0.28%)	5,995 (0.28%)
American Indian or Alaska Native	6,560 (0.57%)	2,630 (0.46%)	676 (0.68%)	1,814 (0.67%)	169 (0.64%)	11,849 (0.56%)
Other Race	35,596 (3.10%)	18,301 (3.23%)	2,343 (2.35%)	9,856 (3.65%)	773 (2.91%)	66,869 (3.16%)
Ethnicity						
Hispanic or Latino	130,735 (11.37%)	63,097 (11.14%)	10,945 (10.99%)	34,869 (12.90%)	3,190 (12.02%)	242,836 (11.49%)
Not Hispanic or Latino	963,391 (83.79%)	473,372 (83.57%)	83,750 (84.08%)	220,462 (81.54%)	21,695 (81.73%)	1,762,670 (83.43%)
Unknown	55,677 (4.84%)	29,982 (5.29%)	4,907 (4.93%)	15,052 (5.57%)	1,659 (6.25%)	107,277 (5.08%)
Characteristics						
Type II Diabetes	468,682 (40.76%)	168,188 (29.69%)	39,004 (39.16%)	187,191 (69.23%)	18,614 (70.13%)	881,679 (41.73%)
Overweight or Obesity	871,514 (75.80%)	444,772 (78.52%)	70,085 (70.37%)	164,734 (60.93%)	15,284 (57.58%)	1,566,389 (74.14%)
Labeled Use						
ADM	513,280 (44.64%)	244,663 (43.19%)	30,354 (30.48%)	270,383 (100.00%)	26,544 (100.00%)	1,085,224 (51.36%)
AOM	246,568 (21.44%)	210,656 (37.19%)	28,261 (28.37%)	n/a	n/a	485,485 (22.98%)
Unknown	389,955 (33.91%)	111,132 (19.62%)	40,987 (41.15%)	n/a	n/a	542,074 (25.66%)
Year						
2019	15,181 (1.32%)	n/a	18,830 (18.91%)	24,176 (8.94%)	5,978 (22.52%)	64,165 (3.04%)
2020	26,108 (2.27%)	n/a	14,119 (14.18%)	25,563 (9.45%)	4,298 (16.19%)	70,088 (3.32%)
2021	57,983 (5.04%)	n/a	16,725 (16.79%)	37,021 (13.69%)	3,614 (13.62%)	115,343 (5.46%)
2022	140,633 (12.23%)	22,198 (3.92%)	20,827 (20.91%)	59,263 (21.92%)	4,385 (16.52%)	247,306 (11.71%)
2023	315,191 (27.41%)	63,179 (11.15%)	18,163 (18.24%)	63,618 (23.53%)	4,046 (15.24%)	464,197 (21.97%)
2024	326,516 (28.40%)	172,638 (30.48%)	6,635 (6.66%)	36,111 (13.36%)	2,746 (10.35%)	544,646 (25.78%)

	Semaglutide	Tirzepatide	Liraglutide	Dulaglutide	Other	Overall
2025	268,191 (23.32%)	308,436 (54.45%)	4,303 (4.32%)	24,631 (9.11%)	1,477 (5.56%)	607,038 (28.73%)
Comorbidity						
Asthma	159,097 (13.84%)	81,371 (14.37%)	14,466 (14.52%)	31,532 (11.66%)	2,407 (9.07%)	288,873 (13.67%)
CKD	138,144 (12.01%)	49,902 (8.81%)	11,007 (11.05%)	47,224 (17.47%)	4,789 (18.04%)	251,066 (11.88%)
COPD	57,041 (4.96%)	22,311 (3.94%)	5,249 (5.27%)	19,511 (7.22%)	1,889 (7.12%)	106,001 (5.02%)
Hyperlipidemia	586,714 (51.03%)	269,186 (47.52%)	41,833 (42.00%)	144,132 (53.31%)	13,946 (52.54%)	1,055,811 (49.97%)
Hypertension	601,331 (52.30%)	267,359 (47.20%)	48,111 (48.30%)	157,263 (58.16%)	15,505 (58.41%)	1,089,569 (51.57%)
Major Depression	134,669 (11.71%)	64,402 (11.37%)	13,179 (13.23%)	24,486 (9.06%)	2,058 (7.75%)	238,794 (11.30%)

Prescribing over time

Overall

We describe the monthly rate of prescriptions by medication and FDA labeled use over time:



First-time

We describe the monthly rate of first-time prescriptions by medication and FDA labeled use over time.



Characteristics of patients by year of first GLP-1 RA use are as follows:

Table 2: Patient Characteristics by Year of First GLP-1 RA Prescription.

	2019	2020	2021	2022	2023	2024	2025
N	64,165 (100.00%)	70,088 (100.00%)	115,343 (100.00%)	247,306 (100.00%)	464,197 (100.00%)	544,646 (100.00%)	607,038 (100.00%)
Age Group							
18-44	11,053 (17.23%)	12,625 (18.01%)	23,623 (20.48%)	60,388 (24.42%)	123,650 (26.64%)	152,111 (27.93%)	176,765 (29.12%)
45-64	34,476 (53.73%)	37,118 (52.96%)	59,654 (51.72%)	125,157 (50.61%)	231,514 (49.87%)	259,634 (47.67%)	276,322 (45.52%)
65+	18,636 (29.04%)	20,345 (29.03%)	32,066 (27.80%)	61,761 (24.97%)	109,033 (23.49%)	132,901 (24.40%)	153,951 (25.36%)
Sex							
Female	35,753 (55.72%)	38,796 (55.35%)	68,535 (59.42%)	158,795 (64.21%)	308,279 (66.41%)	359,682 (66.04%)	394,659 (65.01%)
Male	28,412 (44.28%)	31,292 (44.65%)	46,808 (40.58%)	88,511 (35.79%)	155,918 (33.59%)	184,964 (33.96%)	212,379 (34.99%)
Race							
White	48,645 (75.81%)	52,209 (74.49%)	84,584 (73.33%)	180,316 (72.91%)	332,122 (71.55%)	389,394 (71.49%)	431,038 (71.01%)
Black or African American	9,428 (14.69%)	10,925 (15.59%)	19,150 (16.60%)	39,929 (16.15%)	76,574 (16.50%)	80,954 (14.86%)	85,785 (14.13%)
Asian	1,167 (1.82%)	1,466 (2.09%)	2,518 (2.18%)	5,058 (2.05%)	9,268 (2.00%)	11,333 (2.08%)	13,083 (2.16%)
Unknown	3,202 (4.99%)	3,468 (4.95%)	5,346 (4.63%)	12,146 (4.91%)	27,338 (5.89%)	40,285 (7.40%)	51,339 (8.46%)
Native Hawaiian or Other Pacific Islander	171 (0.27%)	216 (0.31%)	378 (0.33%)	691 (0.28%)	1,236 (0.27%)	1,543 (0.28%)	1,760 (0.29%)
American Indian or Alaska Native	385 (0.60%)	393 (0.56%)	783 (0.68%)	1,590 (0.64%)	2,629 (0.57%)	2,996 (0.55%)	3,073 (0.51%)

	2019	2020	2021	2022	2023	2024	2025
Other Race	1,167 (1.82%)	1,411 (2.01%)	2,584 (2.24%)	7,576 (3.06%)	15,030 (3.24%)	18,141 (3.33%)	20,960 (3.45%)
Ethnicity							
Hispanic or Latino	6,332 (9.87%)	7,373 (10.52%)	12,994 (11.27%)	29,603 (11.97%)	52,723 (11.36%)	64,026 (11.76%)	69,785 (11.50%)
Not Hispanic or Latino	54,599 (85.09%)	59,368 (84.70%)	97,478 (84.51%)	206,971 (83.69%)	389,969 (84.01%)	453,490 (83.26%)	500,795 (82.50%)
Unknown	3,234 (5.04%)	3,347 (4.78%)	4,871 (4.22%)	10,732 (4.34%)	21,505 (4.63%)	27,130 (4.98%)	36,458 (6.01%)
Characteristics							
Type II Diabetes	46,883 (73.07%)	50,515 (72.07%)	74,484 (64.58%)	126,215 (51.04%)	199,240 (42.92%)	196,359 (36.05%)	187,983 (30.97%)
Overweight or Obesity	46,622 (72.66%)	47,243 (67.41%)	81,607 (70.75%)	169,211 (68.42%)	340,413 (73.33%)	414,794 (76.16%)	466,499 (76.85%)
Medication							
Semaglutide	15,181 (23.66%)	26,108 (37.25%)	57,983 (50.27%)	140,633 (56.87%)	315,191 (67.90%)	326,516 (59.95%)	268,191 (44.18%)
Tirzepatide	n/a	n/a	n/a	22,198 (8.98%)	63,179 (13.61%)	172,638 (31.70%)	308,436 (50.81%)
Liraglutide	18,830 (29.35%)	14,119 (20.14%)	16,725 (14.50%)	20,827 (8.42%)	18,163 (3.91%)	6,635 (1.22%)	4,303 (0.71%)
Dulaglutide	24,176 (37.68%)	25,563 (36.47%)	37,021 (32.10%)	59,263 (23.96%)	63,618 (13.70%)	36,111 (6.63%)	24,631 (4.06%)
Other	5,978 (9.32%)	4,298 (6.13%)	3,614 (3.13%)	4,385 (1.77%)	4,046 (0.87%)	2,746 (0.50%)	1,477 (0.24%)
Labeled Use							
ADM	37,337 (58.19%)	48,454 (69.13%)	86,991 (75.42%)	183,457 (74.18%)	269,303 (58.01%)	238,412 (43.77%)	221,270 (36.45%)
AOM	2,244 (3.50%)	3,160 (4.51%)	8,253 (7.16%)	19,742 (7.98%)	81,554 (17.57%)	155,959 (28.63%)	214,573 (35.35%)
Unknown	24,584 (38.31%)	18,474 (26.36%)	20,099 (17.43%)	44,107 (17.83%)	113,340 (24.42%)	150,275 (27.59%)	171,195 (28.20%)
Comorbidity							
Asthma	7,525 (11.73%)	8,674 (12.38%)	15,331 (13.29%)	32,410 (13.11%)	63,072 (13.59%)	76,096 (13.97%)	85,765 (14.13%)
CKD	11,097 (17.29%)	12,743 (18.18%)	19,517 (16.92%)	32,990 (13.34%)	52,824 (11.38%)	58,502 (10.74%)	63,393 (10.44%)
COPD	4,263 (6.64%)	4,894 (6.98%)	7,272 (6.30%)	12,549 (5.07%)	22,317 (4.81%)	25,940 (4.76%)	28,766 (4.74%)

	2019	2020	2021	2022	2023	2024	2025
Hyperlipidemia	38,484 (59.98%)	41,945 (59.85%)	65,603 (56.88%)	124,966 (50.53%)	226,226 (48.73%)	265,353 (48.72%)	293,234 (48.31%)
Hypertension	40,979 (63.87%)	44,063 (62.87%)	69,515 (60.27%)	131,602 (53.21%)	238,385 (51.35%)	272,302 (50.00%)	292,723 (48.22%)
Major Depression	7,399 (11.53%)	8,531 (12.17%)	15,739 (13.65%)	30,889 (12.49%)	52,134 (11.23%)	59,320 (10.89%)	64,782 (10.67%)

60-day dispensing over time

We describe the proportion of patients with any GLP-1 RA prescriptions (first-time and repeat) in a given month who filled any GLP-1 RA in the 60 days following their prescription.



60-day initiation over time

We describe the proportion of patients first-prescribed a GLP-1 RA who filled any GLP-1 RA in the subsequent 60 days over time.



Patient characteristics are given in Table 3:

Table 3: Patient Characteristics by Dispense Status. Dispense status refers to presence of any GLP-1 RA dispense within 60 days of first GLP-1 RA prescription. Table contains the subset of patients with observable 60-day dispense outcomes.

	Dispensed in 60 Days	Not Dispensed in 60 Days	Overall

	Dispensed in 60 Days	Not Dispensed in 60 Days	Overall
N	1,146,610 (100.00%)	821,204 (100.00%)	1,967,814 (100.00%)
Age Group			
18-44	268,706 (23.43%)	247,763 (30.17%)	516,469 (26.25%)
45-64	573,990 (50.06%)	384,872 (46.87%)	958,862 (48.73%)
65+	303,914 (26.51%)	188,569 (22.96%)	492,483 (25.03%)
Sex			
Female	715,260 (62.38%)	555,324 (67.62%)	1,270,584 (64.57%)
Male	431,350 (37.62%)	265,880 (32.38%)	697,230 (35.43%)
Race			
White	814,053 (71.00%)	602,562 (73.38%)	1,416,615 (71.99%)
Black or African American	180,975 (15.78%)	122,983 (14.98%)	303,958 (15.45%)
Asian	25,806 (2.25%)	15,313 (1.86%)	41,119 (2.09%)
Unknown	78,257 (6.83%)	49,614 (6.04%)	127,871 (6.50%)
Native Hawaiian or Other Pacific Islander	3,564 (0.31%)	2,048 (0.25%)	5,612 (0.29%)
American Indian or Alaska Native	6,447 (0.56%)	4,596 (0.56%)	11,043 (0.56%)
Other Race	37,508 (3.27%)	24,088 (2.93%)	61,596 (3.13%)
Ethnicity			
Hispanic or Latino	133,870 (11.68%)	92,589 (11.27%)	226,459 (11.51%)
Not Hispanic or Latino	954,288 (83.23%)	691,567 (84.21%)	1,645,855 (83.64%)
Unknown	58,452 (5.10%)	37,048 (4.51%)	95,500 (4.85%)
Characteristics			
Type II Diabetes	579,647 (50.55%)	260,569 (31.73%)	840,216 (42.70%)
Overweight or Obesity	796,448 (69.46%)	666,039 (81.11%)	1,462,487 (74.32%)
Medication			
Semaglutide	603,174 (52.60%)	478,733 (58.30%)	1,081,907 (54.98%)
Tirzepatide	290,046 (25.30%)	217,356 (26.47%)	507,402 (25.79%)
Liraglutide	52,252 (4.56%)	43,109 (5.25%)	95,361 (4.85%)
Dulaglutide	185,447 (16.17%)	72,493 (8.83%)	257,940 (13.11%)
Other	15,691 (1.37%)	9,513 (1.16%)	25,204 (1.28%)

	Dispensed in 60 Days	Not Dispensed in 60 Days	Overall
Labeled Use			
ADM	711,907 (62.09%)	311,908 (37.98%)	1,023,815 (52.03%)
AOM	208,567 (18.19%)	237,592 (28.93%)	446,159 (22.67%)
Unknown	226,136 (19.72%)	271,704 (33.09%)	497,840 (25.30%)
Year			
2019	37,934 (3.31%)	25,075 (3.05%)	63,009 (3.20%)
2020	41,184 (3.59%)	27,657 (3.37%)	68,841 (3.50%)
2021	68,859 (6.01%)	44,505 (5.42%)	113,364 (5.76%)
2022	154,452 (13.47%)	86,722 (10.56%)	241,174 (12.26%)
2023	278,045 (24.25%)	176,539 (21.50%)	454,584 (23.10%)
2024	294,980 (25.73%)	229,023 (27.89%)	524,003 (26.63%)
2025	271,156 (23.65%)	231,683 (28.21%)	502,839 (25.55%)
Comorbidity			
Asthma	151,074 (13.18%)	122,714 (14.94%)	273,788 (13.91%)
CKD	150,975 (13.17%)	89,939 (10.95%)	240,914 (12.24%)
COPD	61,793 (5.39%)	39,222 (4.78%)	101,015 (5.13%)
Hyperlipidemia	587,695 (51.26%)	415,173 (50.56%)	1,002,868 (50.96%)
Hypertension	605,101 (52.77%)	425,428 (51.81%)	1,030,529 (52.37%)
Major Depression	121,255 (10.58%)	108,986 (13.27%)	230,241 (11.70%)

By Age

As a proxy for Medicare insurance, we segment initiation rate by populations 65+ versus 18-64.



Patient characteristics for patients aged 65+ are given in Table 4:

Table 4: Patient Characteristics by Dispense Status, Age 65+. Dispense status refers to presence of any GLP-1 RA dispense within 60 days of first GLP-1 RA prescription. Table contains the subset of patients with observable 60-day dispense outcomes.

	Dispensed in 60 Days	Not Dispensed in 60 Days	Overall
N	303,914 (100.00%)	188,569 (100.00%)	492,483 (100.00%)
Age Group			
65+	303,914 (100.00%)	188,569 (100.00%)	492,483 (100.00%)
Sex			
Female	169,218 (55.68%)	109,372 (58.00%)	278,590 (56.57%)
Male	134,696 (44.32%)	79,197 (42.00%)	213,893 (43.43%)
Race			
White	235,717 (77.56%)	152,035 (80.63%)	387,752 (78.73%)
Black or African American	35,226 (11.59%)	19,953 (10.58%)	55,179 (11.20%)
Asian	5,267 (1.73%)	2,496 (1.32%)	7,763 (1.58%)
Unknown	18,655 (6.14%)	9,874 (5.24%)	28,529 (5.79%)
Native Hawaiian or Other Pacific Islander	599 (0.20%)	260 (0.14%)	859 (0.17%)
American Indian or Alaska Native	1,259 (0.41%)	704 (0.37%)	1,963 (0.40%)
Other Race	7,191 (2.37%)	3,247 (1.72%)	10,438 (2.12%)

	Dispensed in 60 Days	Not Dispensed in 60 Days	Overall
Ethnicity			
Hispanic or Latino	22,870 (7.53%)	11,477 (6.09%)	34,347 (6.97%)
Not Hispanic or Latino	264,613 (87.07%)	167,795 (88.98%)	432,408 (87.80%)
Unknown	16,431 (5.41%)	9,297 (4.93%)	25,728 (5.22%)
Characteristics			
Type II Diabetes	197,174 (64.88%)	95,208 (50.49%)	292,382 (59.37%)
Overweight or Obesity	201,014 (66.14%)	142,886 (75.77%)	343,900 (69.83%)
Medication			
Semaglutide	163,418 (53.77%)	108,806 (57.70%)	272,224 (55.28%)
Tirzepatide	60,642 (19.95%)	39,181 (20.78%)	99,823 (20.27%)
Liraglutide	10,944 (3.60%)	8,711 (4.62%)	19,655 (3.99%)
Dulaglutide	61,762 (20.32%)	27,753 (14.72%)	89,515 (18.18%)
Other	7,148 (2.35%)	4,118 (2.18%)	11,266 (2.29%)
Labeled Use			
ADM	224,811 (73.97%)	96,449 (51.15%)	321,260 (65.23%)
AOM	19,080 (6.28%)	34,512 (18.30%)	53,592 (10.88%)
Unknown	60,023 (19.75%)	57,608 (30.55%)	117,631 (23.89%)
Year			
2019	10,562 (3.48%)	7,657 (4.06%)	18,219 (3.70%)
2020	11,540 (3.80%)	8,321 (4.41%)	19,861 (4.03%)
2021	18,457 (6.07%)	12,877 (6.83%)	31,334 (6.36%)
2022	37,964 (12.49%)	21,494 (11.40%)	59,458 (12.07%)
2023	72,580 (23.88%)	33,693 (17.87%)	106,273 (21.58%)
2024	77,316 (25.44%)	50,149 (26.59%)	127,465 (25.88%)
2025	75,495 (24.84%)	54,378 (28.84%)	129,873 (26.37%)
Comorbidity			
Asthma	35,289 (11.61%)	23,994 (12.72%)	59,283 (12.04%)
CKD	86,103 (28.33%)	51,334 (27.22%)	137,437 (27.91%)
COPD	31,388 (10.33%)	20,124 (10.67%)	51,512 (10.46%)
Hyperlipidemia	199,996 (65.81%)	134,288 (71.21%)	334,284 (67.88%)
Hypertension	208,416 (68.58%)	138,096 (73.23%)	346,512 (70.36%)
Major Depression	30,689 (10.10%)	22,810 (12.10%)	53,499 (10.86%)

Patient characteristics for patients aged 18-65 are given in Table 5:

Table 5: Patient Characteristics by Dispense Status, Age 18-64. Dispense status refers to presence of any GLP-1 RA dispense within 60 days of first GLP-1 RA prescription. Table contains the subset of patients with observable 60-day dispense outcomes.

	Dispensed in 60 Days	Not Dispensed in 60 Days	Overall
N	842,696 (100.00%)	632,635 (100.00%)	1,475,331 (100.00%)
Age Group			
18-44	268,706 (31.89%)	247,763 (39.16%)	516,469 (35.01%)
45-64	573,990 (68.11%)	384,872 (60.84%)	958,862 (64.99%)
Sex			
Female	546,042 (64.80%)	445,952 (70.49%)	991,994 (67.24%)
Male	296,654 (35.20%)	186,683 (29.51%)	483,337 (32.76%)
Race			
White	578,336 (68.63%)	450,527 (71.21%)	1,028,863 (69.74%)
Black or African American	145,749 (17.30%)	103,030 (16.29%)	248,779 (16.86%)
Asian	20,539 (2.44%)	12,817 (2.03%)	33,356 (2.26%)
Unknown	59,602 (7.07%)	39,740 (6.28%)	99,342 (6.73%)
Native Hawaiian or Other Pacific Islander	2,965 (0.35%)	1,788 (0.28%)	4,753 (0.32%)
American Indian or Alaska Native	5,188 (0.62%)	3,892 (0.62%)	9,080 (0.62%)
Other Race	30,317 (3.60%)	20,841 (3.29%)	51,158 (3.47%)
Ethnicity			
Hispanic or Latino	111,000 (13.17%)	81,112 (12.82%)	192,112 (13.02%)
Not Hispanic or Latino	689,675 (81.84%)	523,772 (82.79%)	1,213,447 (82.25%)
Unknown	42,021 (4.99%)	27,751 (4.39%)	69,772 (4.73%)
Characteristics			
Type II Diabetes	382,473 (45.39%)	165,361 (26.14%)	547,834 (37.13%)
Overweight or Obesity	595,434 (70.66%)	523,153 (82.69%)	1,118,587 (75.82%)
Medication			
Semaglutide	439,756 (52.18%)	369,927 (58.47%)	809,683 (54.88%)
Tirzepatide	229,404 (27.22%)	178,175 (28.16%)	407,579 (27.63%)
Liraglutide	41,308 (4.90%)	34,398 (5.44%)	75,706 (5.13%)
Dulaglutide	123,685 (14.68%)	44,740 (7.07%)	168,425 (11.42%)

	Dispensed in 60 Days	Not Dispensed in 60 Days	Overall
Other	8,543 (1.01%)	5,395 (0.85%)	13,938 (0.94%)
Labeled Use			
ADM	487,096 (57.80%)	215,459 (34.06%)	702,555 (47.62%)
AOM	189,487 (22.49%)	203,080 (32.10%)	392,567 (26.61%)
Unknown	166,113 (19.71%)	214,096 (33.84%)	380,209 (25.77%)
Year			
2019	27,372 (3.25%)	17,418 (2.75%)	44,790 (3.04%)
2020	29,644 (3.52%)	19,336 (3.06%)	48,980 (3.32%)
2021	50,402 (5.98%)	31,628 (5.00%)	82,030 (5.56%)
2022	116,488 (13.82%)	65,228 (10.31%)	181,716 (12.32%)
2023	205,465 (24.38%)	142,846 (22.58%)	348,311 (23.61%)
2024	217,664 (25.83%)	178,874 (28.27%)	396,538 (26.88%)
2025	195,661 (23.22%)	177,305 (28.03%)	372,966 (25.28%)
Comorbidity			
Asthma	115,785 (13.74%)	98,720 (15.60%)	214,505 (14.54%)
CKD	64,872 (7.70%)	38,605 (6.10%)	103,477 (7.01%)
COPD	30,405 (3.61%)	19,098 (3.02%)	49,503 (3.36%)
Hyperlipidemia	387,699 (46.01%)	280,885 (44.40%)	668,584 (45.32%)
Hypertension	396,685 (47.07%)	287,332 (45.42%)	684,017 (46.36%)
Major Depression	90,566 (10.75%)	86,176 (13.62%)	176,742 (11.98%)

Discussion and Conclusion

This analysis summarized GLP-1 RA prescribing trends and patient characteristics from January 2019 to December 2025. During this period 2,185,238 patients were prescribed a total of 11,194,909 total prescriptions. ADMs accounted for 72.7% of prescriptions, and AOMs accounted for 27.3%, among prescriptions where use was known. A larger proportion of ADMs, compared to AOMs, were dispensed within 60 days: 69.5% of first-time ADM prescriptions and 46.7% of first-time AOM prescriptions had a fill within 60 days.

Several limitations of our analysis should be noted. All data are preliminary and may change as additional data are obtained. These findings are consistent with data accessed January 12, 2026. Data presented in this analysis represent raw counts and/or rates, and post-stratification methods have not been conducted. In addition, cohorts with small counts may be suppressed during the de-identification process

leading to the appearance of zero patients for a given time period. Given relatively large numbers of patients prescribed and dispensed GLP-1 RA, we do not expect substantial suppression in the most recent periods. The unknowns in this report either indicate the value was not included in the individual's electronic health record or that it was excluded from the data to protect an individual's identity as a part of Truveta's commitment to privacy (Truveta, 2024). Finally, this report is a description of prescribing trends and patient characteristics only. Results should not be interpreted as causal.

References

Truveta. (2024). Truveta's Approach to Patient Privacy. https://resources.truveta.com/patient-privacy

Centers for disease control and prevention. "National diabetes statistics report". 2020. https://www.cdc.gov/diabetes/data/statistics-report/index.html.

Davies, Melanie J., et al. "Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE diabetes randomized clinical trial." JAMA 314.7 (2015): 687-699.

Davies, Melanie, et al. "Semaglutide 2· 4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial." The Lancet 397.10278 (2021): 971-984.

Hales, Craig M., et al. "Prevalence of obesity and severe obesity among adults: United States, 2017–2018. NCHS Data Brief, no 360." National Center for Health Statistics 360 (2020): 1-7.

Han, Sabrina H., et al. "Public interest in the off-label use of glucagon-like peptide 1 agonists (Ozempic) for cosmetic weight loss: a google trends analysis." Aesthetic Surgery Journal 44.1 (2024): 60-67.

Garvey, W. Timothy, et al. "Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial." The Lancet (2023).

Jastreboff, Ania M., et al. "Tirzepatide once weekly for the treatment of obesity." New England Journal of Medicine 387.3 (2022): 205-216.

Lincoff, A. Michael, et al. "Semaglutide and cardiovascular outcomes in obesity without diabetes." New England Journal of Medicine 389.24 (2023): 2221-2232.

Ussher, John R., and Daniel J. Drucker. “Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action.” Nature Reviews Cardiology 20.7 (2023): 463-474.

Wilding, John PH, et al. “Once-weekly semaglutide in adults with overweight or obesity.” New England Journal of Medicine 384.11 (2021): 989-1002.

Whitley, Heather P., Jennifer M. Trujillo, and Joshua J. Neumiller. “Potential Strategies for Addressing GLP-1 and Dual GLP-1/GIP Receptor Agonist Shortages.” Clinical Diabetes (2023): cd230023.

Yeh, Tzu-Lin, et al. “Effect of glucagon-like peptide-1 receptor agonists on glycemic control, and weight reduction in adults: A multivariate meta-analysis.” PLOS One 18.1 (2023): e0278685.

Acknowledgements

The authors thank Drs. Tricia Rodriguez, Nick Stucky, and Ty Gluckman for their contributions and feedback on describing GLP-1 RA prescribing trends.